Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claus Garbe

Showing results (421-430 of 501) with videos related to

Pageof 51
Sort By:
Science Signaling|January 31, 2013
Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cellsDaniela Beck, Heike Niessner, Keiran S M Smalley, et al.
The Lancet. Oncology|August 3, 2016
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trialPaolo A Ascierto, Grant A McArthur, Brigitte Dréno, et al.
Lancet (London, England)|May 18, 2020
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trialLisa Zimmer, Elisabeth Livingstone, Jessica C Hassel, et al.
The New England Journal of Medicine|June 7, 2011
Ipilimumab plus dacarbazine for previously untreated metastatic melanomaCaroline Robert, Luc Thomas, Igor Bondarenko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2026
Exploratory Analysis of Biomarkers and Treatment Outcomes From the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic MelanomaReinhard Dummer, Shibing Deng, Tao Xie, et al.
Journal of Translational Medicine|July 23, 2018
Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy)Paolo A Ascierto, Igor Puzanov, Sanjiv S Agarwala, et al.
Lancet (London, England)|September 13, 2022
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trialElisabeth Livingstone, Lisa Zimmer, Jessica C Hassel, et al.
European Journal of Cancer (Oxford, England : 1990)|May 17, 2019
Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC)Celeste Lebbe, Claus Garbe, Alexander J Stratigos, et al.
The Lancet. Oncology|March 13, 2017
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trialReinhard Dummer, Dirk Schadendorf, Paolo A Ascierto, et al.
European Journal of Cancer (Oxford, England : 1990)|January 14, 2020
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2019Claus Garbe, Teresa Amaral, Ketty Peris, et al.
Pageof 51

Showing results (421-430 of 501) with videos related to

Sort By:
Pageof 51
Science Signaling|January 31, 2013
Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cellsDaniela Beck, Heike Niessner, Keiran S M Smalley, et al.
The Lancet. Oncology|August 3, 2016
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trialPaolo A Ascierto, Grant A McArthur, Brigitte Dréno, et al.
Lancet (London, England)|May 18, 2020
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trialLisa Zimmer, Elisabeth Livingstone, Jessica C Hassel, et al.
The New England Journal of Medicine|June 7, 2011
Ipilimumab plus dacarbazine for previously untreated metastatic melanomaCaroline Robert, Luc Thomas, Igor Bondarenko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2026
Exploratory Analysis of Biomarkers and Treatment Outcomes From the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic MelanomaReinhard Dummer, Shibing Deng, Tao Xie, et al.
Journal of Translational Medicine|July 23, 2018
Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy)Paolo A Ascierto, Igor Puzanov, Sanjiv S Agarwala, et al.
Lancet (London, England)|September 13, 2022
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trialElisabeth Livingstone, Lisa Zimmer, Jessica C Hassel, et al.
European Journal of Cancer (Oxford, England : 1990)|May 17, 2019
Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC)Celeste Lebbe, Claus Garbe, Alexander J Stratigos, et al.
The Lancet. Oncology|March 13, 2017
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trialReinhard Dummer, Dirk Schadendorf, Paolo A Ascierto, et al.
European Journal of Cancer (Oxford, England : 1990)|January 14, 2020
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2019Claus Garbe, Teresa Amaral, Ketty Peris, et al.
Pageof 51